Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Nature Communications|January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trialOmar Nadeem, Michelle P Aranha, Robert Redd, et al.Nature Communications|February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's MacroglobulinemiaRomanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.Blood|March 12, 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1qRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.Nature Communications|April 8, 2026
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM studyOmar Nadeem, Michelle P Aranha, Robert A Redd, et al.Nature Cancer|August 8, 2025
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursorsElizabeth D Lightbody, Romanos Sklavenitis-Pistofidis, Ting Wu, et al.Cancer Cell|November 15, 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myelomaRomanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, et al.Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.Pageof 2